Trial Profile
An Open-Label Study of Icatibant in Japanese Subjects With Acute Attacks of Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Sponsors Shire
- 21 Sep 2018 Results published in the Media Release
- 21 Sep 2018 According to the Shire media release, company received an approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan. Also, Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for FIRAZYR (icatibant injection), for the acute treatment of hereditary angioedema (HAE) attacks in adult patients.
- 15 Dec 2015 According to a Shire media release, Shire plans to initiate this study in 2016.